Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 4,996 matching trials from the live ClinicalTrials.gov search.

Filters: San Diego, California Clear all

Conditions: Colorectal Polyp, Inflammation, Dietary Intervention, Microbiota, Colorectal Neoplasms, Metabolomics
Interventions: Modified Plant-Based Mediterranean Diet; Dietary Supplement
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Epilepsy
Interventions: radiosurgery, temporal lobectomy; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more

Conditions: Tuberculosis, HIV Infections
Interventions: Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6); Drug · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 21
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 17 more

Conditions: Cystinosis
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Contraception, Breastfeeding
Interventions: Progestin Only Contraceptive Pills; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Sorafenib Tosylate, Sunitinib Malate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2021
U.S. locations: 966
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 601 more

Conditions: Rotator Cuff Tears, Shoulder Injuries, Hallux Valgus, Ankle Arthropathy, Clavicle Fracture
Interventions: Experimental Treatment, Sham Comparator; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Chronic Hepatitis Delta
Interventions: GS-4321, GS-4321 Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Anaheim, California • La Jolla, California • Louisville, Kentucky + 2 more

Conditions: Multiple System Atrophy
Interventions: Rifampicin, placebo; Drug
Lead sponsor: Phillip Low; Other
Eligibility: 30 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • Jacksonville, Florida + 7 more

Conditions: Schizophrenia
Interventions: Physically Ready for Invigorating Movement Every Day (PRIME), Program for Activity, Leisure Skills, and Socialization (PALSS); Behavioral
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 21 Years to 64 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Rett Syndrome
Interventions: TSHA-102; Genetic
Lead sponsor: Taysha Gene Therapies, Inc.; Industry
Eligibility: 6 Years to 21 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 8
States / cities: Duarte, California • La Jolla, California • Oakland, California + 5 more

Conditions: Huntington's Disease
Interventions: sodium phenylbutyrate; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • Iowa City, Iowa + 5 more

Conditions: Schizophrenia
Interventions: SEP-363856; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 5 more

Conditions: Generalized Anxiety Disorder
Interventions: Troriluzole, Placebo; Drug
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 53
States / cities: Little Rock, Arkansas • Colton, California • Encino, California + 48 more

Conditions: Apathy in Dementia
Interventions: CVL-871 1.0 mg, CVL-871 3.0 mg, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 17
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 13 more

Conditions: Healthy Normals
Interventions: Rehabilitation Measurement Tool; Device
Lead sponsor: Reflexion Health, Inc.; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7
Interventions: Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2026
U.S. locations: 910
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 578 more

Conditions: Carcinoma, Hepatocellular, Cirrhosis
Interventions: Abbreviated Magnetic Resonance Imaging with serum AFP, Abdominal Ultrasound Screening with serum AFP; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 4,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 34
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 31 more

Conditions: ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, FANCC Gene Mutation, FANCD2 Gene Mutation, FANCF Gene Mutation, FANCM Gene Mutation, NBN Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, RPA1 Gene Mutation, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib; Other · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1151
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2011
U.S. locations: 52
States / cities: Phoenix, Arizona • Fountain Valley, California • Irvine, California + 43 more

Conditions: Intracranial Meningioma
Interventions: [177Lu]Lu-DOTATATE, Standard of Care treatments; Drug · Other
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 18
States / cities: Irvine, California • La Jolla, California • New Haven, Connecticut + 14 more

Conditions: Benign Prostatic Hyperplasia, Localized Prostate Cancer
Interventions: Robotic Waterjet Treatment; Device
Lead sponsor: PROCEPT BioRobotics; Industry
Eligibility: Up to 80 Years · Male only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: La Mesa, California • Glenview, Illinois • Alexandria, Virginia

Conditions: Ankle Injuries, Syndesmotic Injuries, Ankle Fractures
Interventions: Arthrex Tightrope, Synthes Fibulink; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Huntington Disease
Interventions: RO7234292 (RG6042); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • La Jolla, California • Palo Alto, California + 11 more

Search by objective public record fields.

Impact of Dietary Intervention on Inflammation and Microbiome Composition Post-Colonoscopy

Radiosurgery or Open Surgery for Epilepsy Trial

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis

Progestin-Only Pill Use and Breastfeeding Study

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

Randomized Study of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

Study of Rifampicin in Multiple System Atrophy

Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia

A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

Randomized Trial of Adult Participants With Generalized Anxiety Disorder

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Usability and Reliability of a New Physical Therapy Tool

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Parkinson's Research: The Organized Genetics Initiative

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

Comparing Clinical Outcomes of Suture Button Versus Fibulink Fixation for Acute Ankle Syndesmosis Injuries

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies